A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials by de Sola Llopis, Susana et al.
2	
	
A new cognitive evaluation battery for Down syndrome and its 
relevance for clinical trials 
 
Susana de Sola1,2 *, Rafael de la Torre 1,3,4, Gonzalo Sánchez-Benavides1,5, Bessy Benejam6, Aida 
Cuenca-Royo1,7, Laura del Hoyo1, Joan Rodríguez1, Silvina Catuara-Solarz2, Judit Sánchez-
Gutiérrez8, Ivan Dueñas-Espin1,4, Gimena Hernandez1,11, Jordi Peña-Casanova1,5, Klaus 
Langohr1,9, Sebastia Videla6, Henry Blehaut10, Magi Farre1,11, Mara Dierssen2,12 , and the 
TESDAD Study Group 
1 Human Pharmacology and Clinical Neurosciences Research Group-Neurosciences Program, 
IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain 
2 Cellular & Systems Neurobiology Research Group, Systems Biology Program, Centre for 
Genomic Regulation (CRG), Barcelona, Spain  
3 Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBEROBN), 
Santiago de Compostela, Spain 
4Universitat Pompeu Fabra, CEXS-UPF, Barcelona, Spain 
5Behavioral Neurology and Dementias Research Group, Neurosciences Program, IMIM-Hospital 
del Mar Medical Research Institute, Barcelona, Spain 
6 Fundació Catalana Síndrome de Down, Barcelona, Spain 
7 Epidemiology of Drugs of Abuse Research Group-Epidemiology and Public Health Program, 
IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain 
8 Fundació Privada Espai Salut, Barcelona, Spain 
9Departament of Statistics and Operations Research, Universitat Politècnica de Catalunya, 
Barcelona, Spain. 
10Fondation Jérôme Lejeune, Paris, France 
11Universitat Autónoma de Barcelona (UDIMAS-UAB), Barcelona, Spain 
12 Biomedical Research Centre on Rare Diseases (CIBERER), Valencia, Barcelona, Spain 
 
Corresponding author: 
Susana de Sola, PhD 
Centre for Genomic Regulation (CRG) & IMIM-Hospital del Mar Medical Research Institute  
Parc de Recerca Biomédica de Barcelona (PRBB) 
C/ Doctor Aiguader, 88  
08003 Barcelona, Spain 
sdesola@imim.es 
Tel:  +34-93-3160458 
Fax: +34-93-3160467 
 
3	
	
TESDAD STUDY GROUP.  
Aida Cuenca-Royo, BSc, PhD (Hospital del Mar Medical Research Institute, Barcelona, Spain, 
Neuropsychologist, Site Investigator);  
Alessandro Principe, MD (Hospital del Mar Medical Research Institute, Barcelona, Spain, 
Neurophysiology Section, Site Investigator);  
Bessy Benejam, BSc (Catalan Foundation of Down Syndrome, FCSD, Barcelona, Spain, 
Neuropsychlogist, site investigator);  
Ester Civit, BSc (Hospital del Mar Medical Research Institute, Barcelona, Spain, Site 
Investigator);  
Gimena Hernandez, MD (Hospital del Mar Medical Research Institute, Barcelona, Spain, Site 
Investigator);  
Gonzalo Sánchez-Benavides, BSc, PhD (Hospital del Mar Medical Research Institute, Barcelona, 
Spain, Neuropsychologist, Site Investigator);  
Henri Bléhaut, MD (Jérôme Lejeune Foundation, Paris, France, Site investigator);  
Iván Dueñas, MD (Hospital del Mar Medical Research Institute, Barcelona, Spain);  
Jesús Pujol, MD, PhD (Neurovoxel, Barcelona, Spain, neurologist/neuroimaging, Site 
Investigator); 
Joan Rodríguez, BSc (Hospital del Mar Medical Research Institute, Barcelona, Spain, Study 
Coordinator); 
Jordi Peña-Casanova, MD, PhD (Hospital del Mar Medical Research Institute, Barcelona, Spain, 
Dementia Section, Site Investigator);  
Josep Mª Espadaler, MD, PhD (Hospital del Mar Medical Research Institute, Barcelona, Spain, 
Neurophysiology Section, Site Investigator);  
Judit Sánchez, BSc, Neuropsychlogist (Feskits, Barcelona, Spain, Site Investigator ); 
Katy Trias, BSc (Catalan Foundation of Down Syndrome, FCSD, Barcelona, Spain, Site 
Investigator);  
Klaus Langohr, BSc, PhD (Polytechnics University, Barcelona, Spain, Statistician); 
Laia Roca, BSc (Hospital del Mar Medical Research Institute, Barcelona, Spain, Study Manager);  
Laura Blanco, BSc (Hospital del Mar Medical Research Institute, Barcelona, Spain, 
Neuropsychologist, Site Investigator); 
Laura del Hoyo, BSc (Hospital del Mar Medical Research Institute, Barcelona, Spain, 
Neuropsychologist, Site Investigator); 
Laura Xicota BSc (Hospital del Mar Medical Research Institute, Barcelona, Spain, Site 
Investigator);  
Magí Farré, MD, PhD (Hospital del Mar Medical Research Institute, Barcelona, Spain, co-PI); 
Mara Dierssen, MD, PhD (Centre for Genomic Regulation- CRG of Barcelona, co-PI);  
Rafael de la Torre, PharmD, PhD (Hospital del Mar Medical Research Institute, Barcelona, 
Spain, PI); 
Rut Freixas, BSc (Centre for Genomic Regulation- CRG of Barcelona, Site Investigator);  
Sebastià Videla, MD, PhD (Catalan Foundation of Down Syndrome, FCSD, Barcelona, Spain, 
site investigator); 
Silvina Catuara-Solarz, BSc (Centre for Genomic Regulation- CRG of Barcelona, Site 
Investigator);  
Susana de Sola, BSc, PhD (Hospital del Mar Medical Research Institute, Barcelona, Spain, 
Neuropsychologist, Site Investigator); 
Valérie Legout, BSc (Jérôme Lejeune Foundation, Paris, France, Site Investigator) 
 
1	
4	
	
1. Introduction 1	
 2	
Down Syndrome (DS) is the most common genetic cause of mental retardation (Megarbane et al., 3	
2009), with an incidence of approximately 9.65 for every 10,000 live births in Europe 4	
(Khoshnood et al., 2011). Although most of its phenotypic features are variable, both in 5	
prevalence and expression, the DS neurocognitive profile is characterized by psychomotor delay 6	
and a general, and pronounced, deficit in learning/memory, executive functions, and language 7	
abilities that shape the intellectual disability of the syndrome (Vicari, 2006; Pennington et al., 8	
2003; Rowe et al., 2006; Iacono et al., 2010). The recent flourishing of therapy-oriented research 9	
in DS has led to an increasing number of clinical trials that require validated test batteries to test 10	
treatment efficacy and safety Research in the field of cognitive enhancers for mental health is 11	
moving towards considering key brain networks and specific areas underlying major cognitive 12	
deficits as the main targets for therapeutic intervention, instead of focusing on broad -based 13	
neurotransmitter systems. In parallel, there is the pressing need to update the diagnostic 14	
classification schemes and the neuropsychological assessment methods according to this new 15	
neuroscience-based approach (Insel et al., 2010, 2013). Furthermore, few of the plethora of 16	
methods for cognitive assessment  report clinically significant psychometric data for DS subjects, 17	
and neither do they suitably accommodate the heterogeneous range of impairments experienced 18	
by this population.  19	
 20	
The prevailing methodology used to characterize cognitive functioning compares DS subjects, or 21	
those with other learning disabilities of genetic origin (e.g. Williams-Beuren and Fragile-X 22	
Syndromes) or unknown etiology, to healthy controls of the same “mental age”. The comparison 23	
is assumed to provide an index of global level of mental maturation (Edgin et al., 2010b; Costanzo 24	
et al., 2013a; Finestack and Abbeduto, 2010). These approaches are based on the notion that the 25	
mental maturation rate in subjects with intellectual disability differs substantially from typically 26	
developed subjects of equal chronological age, but should not differ significantly, or only in 27	
certain capacities, when matched for their “mental age” (Costanzo et al., 2013b). Whilst this 28	
perspective has been valuable for characterizing the DS cognitive phenotype, it is not useful for 29	
determining the gap in cognitive performance between DS subjects and healthy adults, which is 30	
the cognitive target we aim for in clinical trials. The few studies that have used an age-matched 31	
healthy population with standard norms have focused on the study of specific cognitive domains 32	
(e.g. language and memory processing), but have not carried out a comprehensive description of 33	
the DS profile (Næss et al., 2011).  34	
 35	
Cognitive-enhancing therapies aim to bring cognitive and functional competence in DS closer to 36	
the standards expected for their chronological age. We propose, therefore, to use an age-matched 37	
healthy control population for the systematic evaluation of the reduction, stabilization, or slowing 38	
of the cognitive and functional performance of DS with respect to therapeutic interventions. From 39	
a clinical point of view, standard norms from healthy subjects provide a feasible and valuable 40	
reference for quantifying the magnitude of cognitive improvement needed for functional changes. 41	
For example, modest cognitive gains related to experimental treatments in DS subjects, which 42	
would be considered of subclinical magnitude in typically developed adults, could imply a mild 43	
but clinically meaningful and significant impact on everyday life functioning in the DS 44	
population, which is harder to determine using mental age or mentally disabled-matched subjects 45	
as a comparison.  46	
 47	
We have developed the TESDAD battery for clinical trials to characterize the cognitive 48	
functioning of young adults with DS, within mild to moderate-severe intellectual disability, using 49	
standard norms from age-matched typically-developed adults as a reference for this 50	
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characterization. The TESDAD battery was used to explore the relative contribution of intellectual 1	
quotient (IQ), gender, and age to neurocognitive variability among DS participants, and to identify 2	
specific relationships between cognitive performance and different aspects of functional outcome 3	
that could potentially serve for expecting functional change in interventional studies.   4	
 5	
 6	
 7	
2. Methods 8	
 9	
2.1. Participants 10	
 11	
Eighty-six young adults of both genders with DS, aged 16 to 34 years, with any of the three DS 12	
genetic variations (trisomy 21, mosaic or translocation) were enrolled in the study, mainly through 13	
the Fundació Catalana de Síndrome de Down (Barcelona) a local foundation specialized in 14	
providing health care services and educational programs to participants with DS and their 15	
families. Subjects with neurological disease other than DS, relevant medical disease, unstable co-16	
morbid mental disorder or currently taking any treatment that could interfere with cognitive 17	
function were excluded from the study. Other exclusion criteria applied to all the participants 18	
were: (i) having suffered from any major illness or undergoing major surgery in the last 3 months 19	
before the study; (ii) new or irregular medication in the month preceding the study; (iii) current 20	
ingestion of vitamin supplements or catechins or AINE in the 2 weeks preceding the study; (iv) 21	
history of gastrointestinal, hepatic, renal or any other problems that may alter absorption, 22	
distribution, metabolism, or excretion of the drug. Genetic variations were documented by 23	
chromosomal analysis.  24	
 25	
2.2. Test procedure and customized neuropsychological test battery 26	
 27	
The study was conducted in accordance with the ethical standards laid down in the Declaration of 28	
Helsinki and approved by the local ethics committee (CEIC-Parc de Salut Mar). The data reported 29	
in the present work correspond to the baseline cognitive performance of a cohort of DS 30	
participants that participated in a clinical trial NCT01699711, that has been registred in 31	
https://clinicaltrials.gov/ct2/show/NCT01699711. Upon arrival at the research center (Hospital del 32	
Mar Medical Research Institute-IMIM), participants, parents and legal guardians (in case of legal 33	
incapacitation) were informed of the ensuing protocol and they gave their written informed 34	
consent before participating.  35	
 36	
At study onset the participants underwent medical examinations and a brief cognitive assessment 37	
to estimate their intellectual disability level based on criteria from the Diagnostic and Statistical 38	
Manual of Mental Disorders, 4th Edition-Text Revision (American Psychiatric Association, 39	
1994). A trained evaluator then individually assessed the participants in a 90-minute session 40	
aimed at exploring a wide range of cognitive and functional domains. The cognitive tests were 41	
presented in a fixed order to allow adequate intervals for delay trials on measures of episodic 42	
memory (see Supplementary Table B.1.). All tasks were carried out in a quiet, comfortable room. 43	
While participants completed the neuropsychological testing, parents, caregivers or legal 44	
guardians answered questionnaires measuring functionality in the participants’ daily lives using 45	
questionnaires for the following domains: adaptive behavior, quality of life (QoL), quality of 46	
sleep, and neuropsychiatric symptoms. Measures of adaptive behavior were obtained with the 47	
adult version of the Adaptive Behavior Assessment System-Second Edition (ABAS-II). Quality of 48	
life was assessed with the parents’/guardians’ version of the Kidscreen-27. Quality of sleep was 49	
explored with The Pittsburgh Sleep Quality Index (PSQI), and neuropsychiatric symptoms were 50	
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assessed with The Neuropsychiatric Inventory (NPI). IQ was estimated using The Kaufman Brief 1	
Intelligence Test (K-BIT). A more detailed description of the complete neuropsychological battery 2	
and references can be found in the supplemental materials (A.1 and A.2). None of the participants 3	
required the presence of their parents or legal guardians to perform cognitive testing.  4	
 5	
2.2.1. Neuropsychological testing 6	
 7	
The following cognitive domains were explored: psychomotor speed, attention, episodic memory, 8	
executive functions, and language. Several tests from the Cambridge Neuropsychological Test 9	
Automated Battery (CANTAB)(Robbins and Sahakian, 1996) were employed in addition to 10	
standard paper and pencil tests. Psychomotor speed was measured with the Motor Screening Test 11	
(MOT, CANTAB). Attention was assessed by means of simple reaction time and span capacity 12	
measures using the Simple Reaction Time task (SRT, CANTAB), the Spatial Span forward recall 13	
(SSP, CANTAB) and the Digit Span forward recall from the Wechsler Adult Intelligence Scale-III 14	
(WAIS-III) that evaluated visual and verbal information, respectively. Measures of visual episodic 15	
memory and learning were obtained using the CANTAB Paired Associates Learning (PAL) and 16	
the Pattern Recognition Memory Test (PRM, CANTAB), and verbal episodic memory using the 17	
Cued Recall Test (CRT). Regarding executive functioning, fractioned components of verbal 18	
fluency, working memory, planning, mental flexibility, and inhibitory control were explored. 19	
Verbal word fluency was measured by means of the semantic fluency word generation task 20	
(animals in one minute). Working memory for visual and verbal information was assessed with 21	
the Spatial Span backward recall (SSP, CANTAB) and the Digits Span backward recall (WAIS-22	
III), respectively. Planning capacity was measured using the Tower of London from Drexel 23	
University (ToLDx) and mental flexibility with the Weigl Color-Form Sort Test. The Cats & 24	
Dogs Test was used to assess response inhibition. Finally, measures of expressive and receptive 25	
language were obtained by means of the Boston Naming Test and the Token Test, respectively. 26	
Only adult versions of the selected cognitive tests were employed with the exception of three 27	
specific tests for adults with intellectual disability due to the complexity of the tasks. These 28	
included the assessment of verbal episodic memory (Cued Recall Test), executive components of 29	
inhibition (Cats and Dogs) and mental flexibility (Weigl Sorting Test). We also administered the 30	
child’s version of the Tower of London-Drexel for the planning task to avoid floor effects. The 31	
cognitive tests were presented in a fixed order to allow adequate intervals for delay trials on 32	
measures of episodic memory. In addition, parallel versions of episodic memory tests were used to 33	
control for learning effects. Regarding the tests selected from the CANTAB, only clinical versions 34	
were administered. 35	
 36	
To perform the comparison of our sample of DS participants with developed healthy ones, raw 37	
test scores from published standard norm databases for subjects of the same age range of our study 38	
(16 to 39 years) were employed. 1/ For the analyses of CANTAB tests, we used data from a 39	
subsample of 51 to 199 control subjects from the CANTAB standard norm database mainly 40	
referenced in Robbins et al., 1997; 1998  (Robbins et al., 1997, 1998)(you can access the 41	
Cambridge Cognition website http://www.cambridgecognition.com/technology and get a practical 42	
demonstration of the tests used). 2/ For the analyses of paper and pencil tests, we used data from a 43	
subsample of 84 to 87 participants (18 to 34 years old) from the Spanish Multicenter Normative 44	
Studies (NEURONORMA young adults Project; (Peña-Casanova et al., 2012). 3/ For the analyses 45	
of TOLDX results, as a child’s version had been used, a subsample of 76 participants (13 to 15 46	
years) was selected (Culbertson and Zillmer, 2005), so that it better matched our sample. Similar 47	
analyses could not be carried out for performance on verbal episodic memory, mental flexibility, 48	
and response inhibition, due to the lack of normative data from typically developed adults for 49	
these tests. 50	
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 1	
This battery was developed, and is currently being used, in a longitudinal, randomized, double 2	
blind, placebo-controlled Phase II trial conducted by our research team in young adults with 3	
Down syndrome (the TESDAD study; (De la Torre et al., 2013)). In the present work, only 4	
baseline neurocognitive results from the TESDAD study are reported.  5	
 6	
3. Statistical analysis  7	
 8	
The first step consisted of a descriptive analysis of the sociodemographic and clinical parameters 9	
of all the participants at baseline. Descriptive analyses were also carried out for all 10	
neuropsychological variables, providing measures of mean, standard deviation, and maximum and 11	
minimum values in the case of quantitative variables. We compared the DS group raw scores of 12	
each cognitive variable to previously published normative data from age-matched healthy 13	
controls. Raw scores of our DS participants could not be compared to normative data for those 14	
tests specifically developed for the assessment of participants with intellectual disability (CRT, 15	
Weigl, Cats & Dogs). In order to quantify and determine the gap between DS and normative 16	
groups, Cohen’s effect size (“Cohen’s d”), which is the difference of the means of two 17	
independent samples divided by the pooled standard deviation,  together with its 95% confidence 18	
interval was calculated for all cognitive variables (Choen, 1988). Effect size differences higher 19	
than one and a half pooled standard deviations (|d|>1.5) in cognitive performance between DS 20	
participants and age-matched normally developed adults were considered key cognitive processes 21	
substantially impaired in DS. In order to assess the severity of impairment the following 22	
categories were established: severe impairment (effect size differences larger than 3 pooled 23	
standard deviations: |d|>3); substantial impairment (|d|>1.5); moderate impairment (|d|>1); and 24	
mild impairment (|d|>0.5). 25	
 26	
To study possible differences in cognitive and functional performance according to IQ, gender, 27	
and age, ANCOVA models were fitted for all neurocognitive measures including these three 28	
variables of interest. For the analyses, the IQ was categorized into two groups: mild/moderate (IQ 29	
> 40) and severe (IQ <40) within the range of mental disability level. Concerning the two 30	
categorical variables, these models provide an adjusted estimation of the mean differences 31	
between persons with DS with IQ < 40 and persons with DS with IQ > 40, on one hand, and 32	
female and male persons with DS, on the other hand. In case of variable age, the models provide 33	
an adjusted estimation of the mean difference associated to one year of age difference in persons 34	
with DS. The differences were considered to be statistically significant if the resulting p value was 35	
less than 0.05. Finally, to explore the relationships between cognitive performance and functional 36	
outcome, the Pearson correlation coefficient was calculated to determine associations between 37	
cognitive variables, IQ (K-BIT standardized score) and functional outcomes of adaptive behavior 38	
and quality of life. We only report moderate and strong correlations (r>0.4). All statistical 39	
analyses were performed with the statistical software package R (The R Foundation for Statistical 40	
Computing), v3.0.2. 41	
 42	
4. Results 43	
 44	
4.1. Descriptive demographic and clinical data of the participants  45	
 46	
Socio-demographic data and clinical parameters of the 86 DS participants are provided in Table 1. 47	
51.2% were male and the mean age was 23.3 years [standard deviation (SD) = 4.3 years; range 16-48	
34 years]. The median IQ for the full sample was 41 [K-BIT standardized score: 105 (SD=17.8; 49	
range 80-180; IQ score (SD)=8.3; range 40-86)], concentrating a slightly higher proportion of 50	
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participants with moderate intellectual disability (IQ>40: 58.1%; n=50) in comparison to those 1	
within the severe mental disability range (IQ<40: 41.9%; n=36). In terms of gender, the median 2	
IQ for males was 40 [K-BIT standardized score: 102 (SD=19; range 80-180)] and 42 for females 3	
[K-BIT standardized score: 108 (SD=16; range 80-154)]. The average years of schooling (regular 4	
school attendance in specialized or non-specialized educational centers) was 13 (SD=1.9; range 5	
10-18). In terms of DS genetic variations, the sample showed the usual proportion for this 6	
population: most participants had full trisomy 21 (simple: 95.3%, n=82), two participants 7	
translocation (2.3%), one partial trisomy (1.1%), and one mosaic (1.1%).  8	
 9	
From the eighty-six participants that participated in the study, 75 were able to reliably complete 10	
all cognitive procedures at baseline. Eleven participants could not perform the entire cognitive 11	
assessment protocol due to cognitive or behavioral alterations that interfered with testing. From 12	
those, 7 participants presented marked language deficit (significant speech and/or comprehension 13	
limitations), and 3 participants presented behavioral disturbances or mental block. One case 14	
showed poor collaboration during the assessment. Only data from these 11 participants for those 15	
tests successfully completed were included in the analyses.  16	
 
Table 1. Sociodemographic characteristics and clinical parameters at baseline 
 
  (n=86) 
Age 23.3 (4.3) 
Gender   
 Female  42 (48.8%) 
 Male 44 (51.2%) 
Education (years) A 13 (1.9) 
Handedness  
 Right  67 (79.8%) 
 Left 17 (20.2%) 
Intellectual disability level  
 Mild/Moderate (IQ > 40) 50 (58.1%) 
 Severe (IQ < 40) 36 (41.9%) 
Intellectual Quotient (IQ)  
IQ 41B 
K-BIT standardized score 105 (17.8) 
Male (standardized; IQ) 102 (19); 40 B 
Female (standardized; IQ) 108 (16); 42 B 
DS genetic variations  
 Trisomy 21  82 (95.3%) 
 Mosaic 1 (1.1%) 
 Translocation 2 (2.3%) 
 Partial 1 (1.1%) 
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Results are presented as mean (standard deviation) for continuous variables and absolute 
frequency (relative frequency) for categorical variables. (A) Average years of school attendance in 
specialized or non-specialized educational centers, (B) Only the median is reported because values 
below 40 cannot be determined exactly. 
 
4.2. Cognitive performance in DS participants compared to standard norms 
  
Descriptive analyses, Cohen effect size differences (d), and confidence intervals (95% CI) of 
cognitive performance in DS and age-matched typically developed adults are summarized in 
Table 2. Results are presented as raw scores of the selected variables. Cohen effect sizes on the 
differences of cognitive performance between DS young adults and euploid subjects revealed the 
following continuum in the magnitude (d) of the deficits in DS: a severe dysfunction of language 
capacity, a substantial deficit on attention span and executive functions, a moderate deficit in 
episodic memory and learning abilities, and mild differences in psychomotor speed (Figure 1). 
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Table 2. Cognitive performance in Down syndrome participants compared to standard norms  1	
(A) Results are presented as mean (standard deviation), (B) Cohen’s effect size. Differences larger than 3 pooled standard deviations: |d|>3); substantial 2	
impairment (|d|>1.5); moderate impairment (|d|>1); and mild impairment (|d|>0.5) (C) Confidence Interval, (D) Milliseconds, (E) Results are compared to 3	
standard norms from the Corsi Block provided by the NEURONORMA young adults Project, (F) Results are compared to standard norms from adolescent 4	
typically developed subjects, ages 13 to 15 years, (G) Seconds 5	
Groups Down syndrome Reference standard norms   
 Mean (SD)A Range (min-max) Age range n Mean (SD) Range (max-min) Age range n Cohen’s-dB 95% CIC 
Attention           
SRT: Simple RT latency (msD) 588.0 (220.0) 302 - 1430 16 – 34 85 -- -- -- -- -- -- 
SRT: Simple RT(%) correct 96.6 (5.7) 68 – 100 16 – 34 85 -- -- -- -- -- -- 
SSP Visual Span  3.2 (1. 5) 0 – 6 16 – 34 86 6.7 (1.3) 3 - 9 16 - 39 199 -2.5 -2.8, -2.2 
Digits Span 2.8 (0.8) 0 – 4 16 – 34 86 6.2 (1.0) 4 - 9 18 -34 84 -3.6 -4.1, -3.1 
Psychomotor Speed           
MOT: Mean latency (ms) 1138.0 (391.0) 576 - 2645 16 – 34 86 928.0 (254.0) 445 - 2204 16 - 39 143 0. 7 0.4, 0.9 
Visual Episodic Memory 
Visual Associative Memory           
PAL: Stages completed 6.7 (1.8) 1 – 8 16 – 34 85 8.0 (0.04) 7 - 8 16 - 39 175 -1.2 -1.5, -0.2 
PAL: First trial memory 11.0 (4.8) 0 – 21 16 – 34 85 21.6 (3.5) 7 - 26 16 - 39 146 -2.6 -3.0, -2.3 
PAL: Total errors adjusted 70.1 (60.90) 6 – 213 16 – 34 85 7. 2 (9.1) 0 - 82 16 - 39 168 1.7 1.4, 2.0 
Visual Recognition           
PRM: (%) Immediate recall 66.9 (19.3) 25 – 100 16 – 34 86 87.8 (12.5) 58.30 - 100 16 - 39 51 -1.2 -1.6, -0.8 
PRM: (%) Delayed recall 61.0 (18.6) 25 – 100 16 – 34 85 -- -- -- -- -- -- 
Executive Functions 
Verbal Fluency           
Semantic Word Fluency 9.4 (4.3) 0 – 21 16 – 34 85 23.6 (4.9) 9 - 34 18 - 34 87 -3.1 -3.5, -2.6 
Working Memory           
SSP Visual Span BackwardsE  2.4 (1.6) 0 – 8 16 – 34 85 5.0 (0.9) 3 – 7 18 - 34 87 -1.9 -2.3, -1.6 
Digits Span Backwards  1.4 (1.2) 0 – 3 16 – 34 86 5.2 (1.3) 3 - 8 18 -34 84 -3.0 -3.4, -2. 6 
Planning F           
ToLDx: Total correct Score 1.7(1.4) 0 – 5 16 – 34 82 4.4 (1.7) -- 13 - 15 76 -1.8 -2.1, -1.4 
ToLDx: Total Move Score 84.7 (39.2) 0 – 170 16 – 34 82 29.0 (13.5) -- 13 - 15 76 1.9 1.5, 2.2 
ToLDx: Probl-solving time (sG) 763.0 (289.0) 0 - 1200 16 – 34 82 214.7 (98.3) -- 13 - 15 76 2.5 2.1, 2.9 
Language           
Comprehension           
Token Test: Total score  19.6 (6.5) 1 – 35 16 – 34 85 35.5 (0.7) 33 - 36 18 – 34 87 -3.4 -3.9, -3.0 
Naming           
Boston Naming: Total score 24.0 (9.5) 0 – 53 16 – 34 82 52.4 (4.3) 39 - 59 18 - 34 87 -3. 9 -4.4, -3.4 
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4.3. Impact of intellectual quotient (IQ), gender, and age on cognitive performance and 1	
functional outcomes  2	
 3	
ANCOVA models were applied to analyze effects of IQ, gender, and age on the baseline cognitive 4	
performance of DS participants, adjusting for co-variables (Tables 3, 4, and 5). IQ was related to 5	
the significant (p<0.05) differences in measures of cognitive capacity between participants of IQ < 6	
40 and those of IQ >= 40, with the exception of performance on the SRT, Digits Span Backwards 7	
and the Weigl Sort Test. These assessing reaction time, verbal working memory and mental 8	
flexibility, respectively. As expected, in all cases higher IQ levels were associated with greater 9	
cognitive attainment irrespective of chronological age or gender (i.e. comparing subjects of equal 10	
age and gender). In addition, significant effects of IQ level were observed in adaptive behavior in 11	
most functional skill areas assessed with the ABAS-II such as Communication, Community Use, 12	
Functional Academics, Home Living, Health and Safety, Self-Direction, Social Skills, and ABAS 13	
total score (p<0.05). Once again, those participants with higher IQ showed better outcomes in 14	
adaptive behavior and thus better competence in daily living. However, no significant effect of IQ 15	
emerged on the Kidscreen-27 (p>0.05) which assessed different aspects of quality of life.  16	
 17	
Concerning gender, significant differences between men and women were mainly observed in 18	
cognitive performance and less in functional outcomes. Women performed significantly better 19	
than men of the same age and IQ in most cognitive tests (Tables 3, 4, and 5), with the most 20	
consistent differences occurring in episodic memory and executive functioning (Figure 2). 21	
Women also responded better in episodic memory tests, in particular visual associative memory 22	
(PAL) and free recall of verbal information (CRT) (p<0.05), but not in visual memory recognition 23	
(PRM; p>0.05). Concerning executive functions, women showed significantly better performance 24	
(p<0.05) in cognitive flexibility and planning. Furthermore, they exhibited higher scores in 25	
receptive language and attention measures of span capacity, and better accuracy in the simple 26	
reaction time task (p<0.05). Gender-related differences were also observed in the functional 27	
domain, with women having a significantly better performance than men in adaptive behavior, 28	
specifically in Functional Academic (emergent literacy and numeracy basics for current life use) 29	
(p<0.05), but described lower health perception regarding their physical wellbeing as reported by 30	
parents on the Kidscreen-27 (Kidscreen 27-Physical; p=0.04). Overall, these results indicate that 31	
gender exerts significant effects on cognitive and functional capacities in DS participants, 32	
favoring women against men in cognitive functioning and adaptive skills but not in QoL. 33	
  34	
Significant negative trends rarely emerged on quality of life outcomes linked to the effect of age 35	
in DS participants after adjusting for IQ and gender. Age did not affect adaptive behaviours, nor 36	
most measures of quality of life significantly. However, age did affect psychological well being, 37	
which affected total quality of life (p<0.03). Parents responding to the Kidscreen 27 Psychological 38	
and Total score items indicated poorer psychological wellbeing and overall health perception as 39	
the children grew older.  40	
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Table 3. Impact of intellectual quotient, gender, and age on attention, psychomotor, memory, and language performance in Down syndrome 1	
participants. 2	
(A) Estimated mean difference between persons with DS with IQ < 40 and persons with DS with IQ > 40 adjusted for gender and age, (B) 3	
Confidence Interval, (C) Estimated mean differences between female and male persons with DS adjusted for IQ and age, (D) Estimated mean 4	
differences associated to one year of age difference in persons with DS adjusted for IQ and gender, (E) Milliseconds, (*) Significant estimated 5	
effects of the variable of interest (p<0.05), (**) Significant estimated effects of the variable of interest (p<0.01), (***) Significant estimated 6	
effects of the variable of interest (p<0.001), (+) Marginal non-significant estimated effects of the variable of interest. 7	
Down syndrome Intelligence Quotient (<40 vs.≥40) Gender (female vs. male) Age EstimateA 95% CIB p-value EstimateC 95% CI p-value EstimateD 95% CI p-value 
Attention          
SRT: Simple RT latency (msE) 57.2 [-39.1; 153.6] 0.24 -37.7 [-134.2; 58.8] 0.44 8.68 [39.1; 153.6] 0.13 
SRT: Simple RT(%) correct -1.9 [-4.3; 0.5] 0.12 2.8 [0.3; 5.2] 0.02* -0.25 [-0.5; 0.03] 0.08 
SSP Visual Span -0.8 [-1.4;- 0.2] 0.01* 0.7 [0.1; 1.3] 0.02* -0.03 [-0.0; 0.03] 0.34 
Digits Span -0.4 [-0.7;- 0.03] 0.03* 0.3 [0.01; 0.7] 0.04* 0.02 [-0.01; 0.06] 0.20 
Psychomotor Speed          
MOT: Mean latency (ms) 176.1 [9.3; 342.9] 0.03* 3.6 [-164.2; 171.4] 0.96 15.7 [-4.2; 35.5] 0.12 
Episodic Memory          
Visual Associative Memory          
PAL: Stages completed -1.0 [-1.8;-0.3] 0.006** 1.30 [0.6; 2.0] 0.001** 0.02 [-0-06; 0.10] 0.61 
PAL: First trial memory -1.8 [-3.7; 0.2] 0.07+ 3.47 [1.5; 5.4] 0.001** 0.002 [-0.2; 0.2] 0.98 
PAL: Total errors adjusted 35.1 [11.8; 58.4] 0.004** -52.24 [-75.6;-28.9] <0.001*** 0.1 [-2.7; 2.9] 0.94 
Visual Recognition          
PRM: (%) Immediate recall -12.1 [-20.2; -4.1] 0.004** 4.25 [-3.8; 12.3] 0.29 -0.6 [-1.6; 0.3] 0.20 
PRM: (%) Delayed recall -8.0 [-16.0; 0.01] 0.05+ 2.04 [-6.0; 10.1] 0.61 -0.7 [-1.6; 0.3] 0.15 
Verbal Episodic Memory          
CRT:A1-A3 Free immediate recall -2.5 [-5.0; 0.1] 0.05+ 3.6 [1.0; 6.1] 0.007** 0.1 [-0.2; 0.4] 0.68 
CRT:A1-A3 Total immediate recall -0.7 [-1.5; 0.2] 0.11 0.8 [-0.01; 1.7] 0.05+ 0.03 [-0.1; 0.1] 0.48 
CRT: Free delayed recall -0.9 [-2.0; 0.2] 0.11 1.5 [0.4; 2.6] 0.008** 0.1 [-0.1; 0.2] 0.33 
CRT: Total delayed recall -0.1 [0.4; 0.2] 0.45 0.05 [-0.2; 0.3] 0.68 0.02 [-0.01; 0.05] 0.24 
Language          
Comprehension          
Token Test: Total score -5.6 [-8.1; -3.0] <0.001*** 3.25 [0.7; 5.8] 0.01* 0.01 [-0.3; 0.3] 0.97 
Naming          
Boston Naming: Total score -9.9 [-13.6; -6.1] <0.001*** 2.22 [-1.5; 5.9] 0.2 -0.1 [-0.6; 0.3] 0.59 
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 Table 4. Impact of intellectual quotient (IQ), gender, and age on executive functioning in Down syndrome participants 1	
 2	
 3	
(A) Estimated mean difference between persons with DS with IQ < 40 and persons with DS with IQ > 40 adjusted for gender and age, (B) 4	
Confidence Interval, (C) Estimated mean differences between female and male persons with DS adjusted for IQ and age, (D) Estimated mean 5	
differences associated to one year of age difference in persons with DS adjusted for IQ and gender, (E) Milliseconds, (*) Significant estimated 6	
effects of the variable of interest (p<0.05), (**) Significant estimated effects of the variable of interest (p<0.01), (***) Significant estimated 7	
effects of the variable of interest (p<0.001), (+) Marginal non-significant estimated effects of the variable of interest. 8	
 9	
 Down syndrome 
 
Intelligence Quotient (<40 vs. ≥40) Gender (female vs. male) Age 
EstimateA 95% CIB p-value EstimateC 95% CI p-value EstimateD 95% CI p-value 
Executive Functions 
Verbal Fluency  
 
  
 
  
 
 
Semantic Word Fluency -2.6 [-4.4; -0.8] 0.006** -0.1 [-1.9; 1.7] 0.87 0.1 [-0.1; 0.3] 0.29 
Working Memory          
SSP Visual Span Backwards  -0.8 [-1.4; -0.1] 0.02* 0.7 [0.05; 1.4] 0.03* 0.03 [-0.04; 0.1] 0.42 
Digits Span Backwards -0.3 [0.86; 0.15] 0.16 0.43 [-0.1; 0.9] 0.09 -0.01 [0.04; 0.6] 0.64 
Planning          
ToLDx: Total correct score -1.0 [-1.6; -0.5] <0.001*** 0.9 [0.4;1.5] 0.002** -0.03 [-0.1; 0.03] 0.36 
ToLDx: Total move score 26.3 [10.0; 42.7] 0.002** -20.9 [-37.2; -4.6] 0.01* 0.9 [-1.0; 2.8] 0.33 
ToLDx: Problem-solving time (sE) 180.3 [58.2; 302.4] 0.004** -143.9 [-265.6; -22.1] 0.02* 9.2 [-5. 1; 23.5] 0.20 
Mental flexibility          
Weigl Sort Test: Total score -0.3 [-1.0; 0.3] 0.32 1.2 [0.5; 1.9] 0.001** -0.02 [-0.1; 0.1 0.62 
Inhibition          
Cats and Dogs: Total time (s) 7.6 [0.6; 14.7] 0.03* -2.4 [-9. 5; 4.6] 0.48 0.2 [-0.7; 1.0] 0.66 
Cats and Dogs: Correct score -0.6 [-1.1; -0.1] 0.02* -0.01 [-0.5; 0.5] 0.96 -0.02 [0.1; 0.03] 0.44 
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Table 5. Impact of intellectual quotient (IQ), gender, and age on functional outcomes in Down syndrome participants 1	
 2	
 Down Syndrome 
Intelligence Quotient (<40 vs. ≥40) Gender (female vs. male) Age 
 EstimateA 95% CIB p-value EstimateC 95% CI p-value EstimateD 95% CI p-value 
Adaptive Behavior          
ABAS-Communication  -8.7 [-13.9;-3.6] 0.001** 4.2 [-1.0; 9.4] 0.11 0.1 [-0.7;0.8] 0.82 
ABAS-Community Use -9.7 [-15.0;-4.4] <0.001*** 2.8 [-2.5;8.1] 0.29 0.5 [-1.1;1.1] 0.13 
ABAS-Functional Academics -13.3 [-20.4;-6.3] <0.001*** 9.0 [1.9;16.1] 0.01* 0.1 [-0.1;1.0] 0.77 
ABAS-Home Living -5.6 [-10.6;-0.6] 0.02* 4.2 [-0.8;9.3] 0.09 0.4 [-0.2;1.0] 0.17 
ABAS-Health & Safety -5.8 [-9.7;-1.8] 0.005** 0.5 [-3.5;4.5] 0.81 0.2 [-0.3;0.7] 0.42 
ABAS-Leisure -2.5 [-7.6;2.5] 0.32 1.2 [-3.8;6.3] 0.62 -0.2 [-0.8;0.4] 0.50 
ABAS-Self-Care -1.5 [-5.1;2.2] 0.42 2.4 [-1.3;6.0] 0.20 0.03 [-0.4;0.5] 0.85 
ABAS-Self-Direction -8.7 [-14.8; -2.5] 0.006** 4. 9 [-1.2;11.0] 0.11 0.2 [-0.6; 0.9] 0.64 
ABAS-Social skills -7.6 [-12.4;-2.8] 0.002** 1.8 [-2.9;6.6] 0.44 -0.5 [-1.0;0.1] 0.09 
ABAS-Work --  -- --  -- --  -- 
ABAS-Total score -63.4 [-100.4; -26.4] 0.001** 31.1 [-6.1;68.3] 0.10 0.8 [-3.6;5.2] 0.71 
Quality of Life          
Kidscreen 27-Physical 0.6 [-1.1;-2.2] 0.49 -1.7 [-3.3;-0.05] 0.04* -0.2 [-0.4;0.03] 0.09 
Kidscreen 27-Psychological  0.5 [-1.2;-2.3] 0.53 0.2 [-1.5;1.9] 0.82 -0.2 [-0.4;-0.01] 0.03* 
Kidscreen 27-Autonomy & 
Parents 0.1 [-1.1; 1.4] 0.80 1 [-0.3;2.3] 0.11 -0.05 [-0.2;0.1] 0.46 
Kidscreen 27-Peers & Social  0.5 [-1.4; 2.4] 0.60 0.9 [-1.0; 2.8] 0.35 -0.05 [-0.3;0.2] 0.66 
Kidscreen 27-School  ---  --- ---  --- ---  --- 
Kidscreen 27-Total score 2.8 [-3.9; 9.6] 0.39 -1.0 [-7.6;5.6] 0.75 -0.9 [-1.7;0.1] 0.03* 
 3	
(A) Estimated mean difference between persons with DS with IQ < 40 and persons with DS with IQ > 40 adjusted for gender and age, (B) 4	
Confidence Interval, (C) Estimated mean differences between female and male persons with DS adjusted for IQ and age, (D) Estimated mean 5	
differences associated to one year of age difference in persons with DS adjusted for IQ and gender, (E) Milliseconds, (*) Significant estimated 6	
effects of the variable of interest (p<0.05), (**) Significant estimated effects of the variable of interest (p<0.01), (***) Significant estimated 7	
effects of the variable of interest (p<0.001), (+) Marginal non-significant estimated effects of the variable of interest. 8	
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4.4. Relationship between cognitive deficits and functional outcome 1	
 2	
The Pearson correlation coefficient was calculated to assess the relationships between cognition 3	
and functionality, in order to identify meaningful cognitive measures of potential change for 4	
clinical trials. Moderate associations emerged among a wide spectrum of cognitive measures and 5	
IQ with specific adaptive skills, or the total score in the ABAS-II, while no association was 6	
detected with quality of life measures.  7	
 8	
The strongest associations were found between cognitive performance and functional academic 9	
skills (ABAS-II). Positive associations emerged between Functional Academics and measures of 10	
receptive and expressive language (Token Test: r= 0.65, [0.51, 0.76]; Boston Naming: r= 0.42, 11	
[0.22, 0.58]) and executive components of verbal fluency (Semantic word fluency: r= 0.40, [0.20, 12	
0.56]). Positive associations were also found for working memory for visual and verbal 13	
information (SSP span backwards: r= 0.47, [0.29, 0.62]; Digits span backwards: r= 0.48, [0.30, 14	
0.63]), planning (ToLDx Total correct score: r= 0.53, [0.35, 0.67]), attention span for visual and 15	
verbal information (SSP span: r= 0.56, [95%-CI: 0.39, 0.69]; Digits span: r= 0.46, [0.28, 0.62]), 16	
and memory recognition for immediate and delayed recall of visual information (PRM (%) 17	
immediate recall: r= 0.45, [0.26, 0.60]; PRM (%) delayed recall: r= 0.48, [0.29, 0.63]). Negative 18	
associations were found between Functional Academics and error rate in the visual associative 19	
learning task (PAL total errors adjusted: r= -0.56, [-0.69, -0.39]) and planning accuracy deficits 20	
(ToLDx Total move score: r= -0.51, [-0.66, -0.33]). These results indicate that higher attainment 21	
in functional academic skills (emergent literacy and numeracy basics for current life use) could be 22	
strongly linked to a more efficient overall cognitive functioning in DS participants. In addition, a 23	
positive consistent association emerged between Functional Academics and IQ (IQ: r= 0.52, 24	
[0.35, 0.66]). These results confirm previous assumptions, and suggest that specific cognitive 25	
measures are potentially good end-point measures for estimating changes in functional outcome in 26	
clinical trials.  27	
 28	
Communication and Community use subscales of the ABAS-II also correlated consistently with 29	
cognitive attainment. Positive correlations were found between communicative abilities and visual 30	
attention span (SSP span: r= 0.40, [0.20, 0.56]), receptive and expressive language (Token Test: 31	
r= 0.52, [0.34, 0.66]; Boston Naming: r= 0.41, [0.21, 0.58]). In addition, a negative association 32	
was observed between ability to communicate and the number of errors performed during visual 33	
associative learning (PAL total errors adjusted: r= -0.46, [-0.61, -0.27]). Community use was 34	
mainly related to cognitive measures of receptive language (Token Test: r= 0.52, [0.30, 0.63]) and 35	
executive components of working memory for visual and verbal information (SSP span 36	
backwards: r= 0.43, [0.24, 0.59]; Digits span backwards: r= 0.41, [0.21, 0.57]) and planning 37	
(ToLDx Total correct score: r= 0.40, [0.19, 0.56]). In all cases, a higher performance in specific 38	
cognitive tests was consistently related to a greater ability to communicate in daily life and higher 39	
independent functioning within the community.  40	
 41	
Finally, language comprehension emerged as having the most consistent association with the 42	
overall score in adaptive behavior (ABAS Total Score) (Token Test: r= 0.52, [0.35, 0.66]). Other 43	
cognitive measures were consistently correlated with the ABAS Total Score such as visual 44	
attention span (SSP span: r= 0.40, [0.20, 0.56]) and executive components of visual working 45	
memory (SSP span backwards: r= 0.41, [0.22, 0.57]) and planning (ToLDx Total correct score: r= 46	
0.41, [0.21, 0.58]; ToLDx Total move score: r= -0.48, [-0.63, -0.29]). These results indicate that 47	
better language comprehension, attention, and executive functioning are the cognitive capacities 48	
more closely related to higher competence in overall adaptive skills and, therefore, in everyday 49	
life independence for DS participants. 50	
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5. Discussion 1	
 2	
This study proposes a new neurocognitive battery for clinical trials in DS adults (the TESDAD 3	
battery), using chronologically age-matched fully-developed subjects for comparison as a more 4	
useful approach for the characterization of the DS cognitive profile. This battery also provides 5	
clinically useful measures closely linked to prefrontal-temporal brain networks and to functional 6	
competence in everyday life following interventional studies. Finally, our study emphasizes the 7	
need to determine the modulation effects of intellectual quotient, gender, and age on cognitive 8	
treatments.  9	
 10	
5.1. Magnitude of cognitive deficits in DS adults 11	
 12	
The results of this study support the demonstration (Laws and Bishop, 2004; Abbeduto et al., 13	
2001; Næss et al., 2011) that language impairment  is the strongest cognitive disturbance in young 14	
DS adults with receptive abilities being more preserved than expressive skills. In addition, and as 15	
previously reported, the relative strength of visuospatial processing over verbal tasks suggests that 16	
language impairment is the primary landmark of global intellectual impairment in DS (Lanfranchi 17	
et al., 2004; Edgin et al., 2010b). After language, attention and executive functions differed more 18	
from standard norms, with verbal span capacity and verbal fluency presenting the strongest 19	
deficiencies, followed by working memory; in contrast, planning was relatively more preserved. 20	
These results concur with the portrayal of a broad, marked dysexecutive syndrome in DS 21	
(Lanfranchi et al., 2010; Rowe et al., 2006) probably due to the reduced size of the prefrontal 22	
cortex (Contestabile et al., 2010; Lott and Dierssen, 2010), in particular of the anterior cingulate 23	
gyrus, medial, and dorsolateral prefrontal cortices as reported in neuroimaging studies of DS 24	
adults (Raz et al., 1995; White et al., 2003; Carducci et al., 2013). Areas such as these actively 25	
contribute to mnemonic processing and executive control in euploid subjects (Blumenfeld et al., 26	
2011; Braver, 2001; Wager and Smith, 2003), thus generalized impairment of high order frontal-27	
dependent processes, together with language, represent a crucial target for therapeutic intervention 28	
in DS.  29	
 30	
Overall performance in episodic memory was also poor although superior to language, attention, 31	
and executive functions. It is noteworthy that our results showed a better preservation of 32	
hippocampal-dependent memory processes, such as storage and consolidation, compared to 33	
frontal-mediated processes (information coding, retrieval strategies and attention control) in DS. 34	
Findings substantiated by the higher performance exhibited in the recognition and cued recall 35	
trials as compared to free recall, and by the higher ratio of perseverative errors compared to 36	
intrusions in the verbal learning task (see supplemental results). This mnemonic profile indicates 37	
that poor monitoring and executive control, rather than storage difficulties, are mainly responsible 38	
for poor memory performance. In this regard, structural neuroimaging studies have related 39	
impaired memory performance in DS adults with reductions in the prefrontal, hippocampus, and 40	
parahippocampal areas of these subjects (Beacher et al., 2005; Krasuski et al., 2002; Teipel et al., 41	
2004). Postmortem histological studies have, moreover, consistently demonstrated that the 42	
dendritic morphology of hippocampal neurons is compromised in DS adult brains (Ferrer and 43	
Gullotta, 1990; Takashima et al., 1994). In summary, our results indicate executive dysfunction as 44	
a major factor underlying memory impairment in DS. Thus, effective therapies targeting 45	
prefrontal-dependent executive functions in this population would enhance cognitive performance.  46	
 47	
48	
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5.2. Effects of IQ, gender, and age on cognitive and functional outcomes in DS 1	
 2	
We explored the association of clinical and sociodemographic variables such as IQ, gender, and 3	
age with cognitive and functional performance in DS. Our regression analyses, in concurrence 4	
with other authors, revealed that the explanation for the extensive variability found in the 5	
neurocognitive performance of DS adults lies in the primary variable of the IQ level. The most 6	
consistent associations with IQ were found with language, its use in everyday functioning 7	
(learning of literacy basics, communication skills, social abilities, and efficient use of community 8	
resources), and with global adaptive competence. No effect of IQ was observed, however, on 9	
quality of life outcomes. A finding that could partly be explained by the fact that in euploids, 10	
emotional aspects are more closely related to QoL perception than IQ (Takeuchi et al., 2013). The 11	
use of parent-proxy measures for determining QoL perception in DS is, nevertheless, a surrogate 12	
and a probably biased outcome based on QoL self-perception in these subjects.  13	
 14	
It is noteworthy that gender showed a widespread influence on cognitive variables whilst its 15	
impact on functional outcomes was minor. From our analyses we can conclude that men with DS 16	
perform at a significantly poorer level than DS women, in particular with respect to episodic 17	
memory and executive processing. They also exhibit poorer functional academic skills in 18	
everyday life, but present a higher QoL perception concerning their physical wellbeing. Although 19	
the differences observed in cognitive performance between genders are mild, they may explain the 20	
higher IQ level and better competence exhibited by women in everyday functioning, in particular 21	
related to command of language. Other studies have also reported that women with trisomy 21 22	
display a higher level of cognitive and adaptive functioning than DS men (Lund, 1988; Määttä et 23	
al., 2006). Taken together, these findings suggest that gender may exert a relevant modulating 24	
effect on cognitive functioning in DS participants favoring women, which is not the case in 25	
healthy participants. The poorer QoL status in young women with DS compared to men, 26	
especially with respect to their physical wellbeing, may not be characteristic of DS associated 27	
with gender, since it has also been reported in woman from euploid population (Michel et al., 28	
2009; Torsheim et al., 2006).  29	
 30	
The impact of age on neurocognitive outcomes was negligible and restricted to QoL perception. In 31	
a similar manner to healthy adolescents and young adults, increasing age in DS participants was 32	
associated with a decline in QoL, in spite of the fact that women reported poorer outcomes 33	
compared to men (Bisegger et al., 2005; Michel et al., 2009). Thus, lower QoL with increasing 34	
age is not a distinctive trend in DS. No significant impact of age was found on cognitive and 35	
adaptive behavior outcomes, probably due to the age range of our sample (16 to 34 years old), 36	
representative of late adolescence and adulthood when the negative consequences of premature 37	
aging upon cognition and everyday life competence have not yet been detected. Our results 38	
suggest that during this period overall cognitive capacity in DS adults has probably reached a 39	
plateau, similar to the scenario of normally developed adults who reach their peak performance 40	
between 18 to 30 years of age (Peña-Casanova et al., 2012). Taken together, our results emphasize 41	
the need to explore the modulating effects of IQ, gender, and age on cognitive enhancing 42	
treatments in the DS population. 43	
 44	
5.3. Relationship to functional outcome in DS participants for interventional studies  45	
 46	
We explored the associations between cognitive performance, IQ, and functional outcomes of 47	
adaptive behavior and QoL in DS. The aim was to identify specific relationships between 48	
cognitive performance and different aspects of functional outcome that could potentially serve for 49	
expecting functional change following interventional studies. Cognitive-related outcomes were 50	
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closely linked to functional aspects of language and global adaptive competence in everyday life. 1	
It is worth mentioning that auditory comprehension and functional academic measures have a 2	
great potential as end-point measures of therapeutic intervention for clinical trials: the former as a 3	
cognitive key target for therapeutic intervention, and the latter as a primary functional outcome 4	
measure of clinical efficacy.  5	
 6	
According to the results obtained in the regression analysis, it could be argued that IQ could be a 7	
good predictor of functional outcome for longitudinal interventional studies. Specific cognitive 8	
capacities, however, showed consistent associations with functional outcomes in the univariate 9	
analysis. IQ remains stable during adult life whilst cognitive capacities underlying intellectual 10	
status, such as attention, memory, language, and executive functions, are dynamic throughout the 11	
lifespan. These changes in cognitive capacity provide greater sensitivity for assessing the efficacy 12	
of therapeutic interventions. In addition, these cognitive capacities can be precisely measured with 13	
specific tests that are sensitive to clinical and subclinical changes. The fact that these cognitive 14	
measures are considered a proxy of such subclinical changes, closely related with the abnormal 15	
functioning of prefrontal-temporal brain networks, is extremely important when testing new 16	
therapeutic strategies for mental disability. Currently, a major caveat of clinical trials targeting 17	
functional change in DS is that follow-up periods tend to be too short (less than 12 months on 18	
average), while improvements in complex functional skills in DS require longer periods (Boada et 19	
al., 2012; Costa, 2011) We agree with this view but suggest that subclinical cognitive gains related 20	
to positive pharmacological and/or behavioural interventions in DS may be sufficient for a mild, 21	
but significant, impact on everyday life functioning, similar to what we can expect in other 22	
pathological conditions such as AD (Insel et al., 2013). Studies with extended follow-up periods 23	
under active treatment are needed to probe our hypotheses and ensure the validity of the proposed 24	
linkages as clinically meaningful for estimating functional change in interventional studies.  25	
 26	
5.4. Limitations  27	
 28	
Several limitations should be considered when interpreting the results of our study. First, the 29	
neurocognitive assessment tools we employed may have influenced the DS cognitive profile 30	
observed. The majority of the tests included in our TESDAD battery are, nevertheless, recognized 31	
as valid and feasible for tracking cognitive deficits in pathological conditions (Juncos-Rabadán et 32	
al., 2014; Ersche et al., 2012), they are well standardized and extensively normalized, and 33	
acceptable for DS participants with mild to moderate mental disability (De la Torre et al., 2013; 34	
Devenny et al., 2002; Ball et al., 2008) . Floor effects were observed for the verbal span (Digits) 35	
and mental flexibility (Weigl Sort Test) tasks, whereas ceiling effects where only shown in the 36	
response inhibition test regarding task accuracy but not for time of response (Cats & Dogs). These 37	
findings suggest that the former tasks could be replaced whereas the later could be extended in 38	
order to increase its difficulty. One of the few commonly used cognitive batteries is the Arizona 39	
Battery (ACTB), developed for school age children and young adults with DS (age range 7 to 30 40	
years), employing the mental-age matched procedure (Edgin et al., 2010a). The principal 41	
differences between the ACTB and the TESDAD battery are that TESDAD allows a more 42	
thorough, direct cognitive assessment of the main mnemonic and executive components with 43	
language being a key domain, whereas ACTB includes a deeper assessment of executive-44	
behavioral dysfunction using questionnaires for parents. In addition, the TESDAD was also 45	
designed to be sensitive to mild cognitive impairment, making this tool potentially valid for 46	
capturing deterioration in the prodromal stage. Another limitation is that the TESDAD only 47	
explores “cool-cognitive functions”, whereas “hot-cognitive processing” involving emotional, 48	
motivational, and rewarding aspects are omitted. We focused our assessment on cool-conscious 49	
high reasoning processes, in particular on executive and mnemonic processing supported by the 50	
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hippocampus and frontal cortices, because preclinical and clinical evidence consider those to be 1	
critical targets for therapeutic intervention in DS. Nonetheless, the TESDAD Battery should 2	
undergo further modifications to integrate new feedback provided by future preclinical and 3	
clinical evidence. Another drawback is that IQ estimation within the lowest range (IQ<40) could 4	
not be exactly determined with the K-BIT. The lack of an overall composite score integrating 5	
cognitive and functional outcomes is another important limitation, ongoing issue for the TESDAD 6	
battery. This comprehensive score would be a valuable asset for globally evaluating treatment 7	
effects in longitudinal studies. Finally, the lack of a test-retest reliability assessment of the overall 8	
battery is another important drawback. Nonetheless, the selection of tests was based upon 9	
previous reliability studies carried for each of these tools (Strauss et al., 2006).  10	
 11	
6. Conclusion 12	
 13	
In summary, the TESDAD battery is a useful tool for a standardized neurocognitive assessment of 14	
DS in clinical trials. The most relevant features of this battery include a chronological age-15	
matched approach, high sensitivity for detecting mild	to	moderate	cognitive	deficits,	and	a	16	
strong	relationship	to	clinically	relevant	functional	measures.	These	features	make	the	17	
battery	suitable	for	capturing	changes	derived	from	therapy	which	allow	its	efficacy	to	be	18	
established.  19	
 20	
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Figure 1:  Radar plot representing the severity of cognitive impairment in Down syndrome (DS) 1	
compared to age-matched typically developed adults on attention, memory, language and 2	
executive functioning components. Axis values indicate the absolute value of Cohen´s effect size 3	
(d) for the differences between both populations. For this purpose, the performance of the 4	
participants with DS has been standarized to 1 which is equivalent to an effect size of d=0.  DS 5	
adults show a severe dyfunction of language capacity (|d|>3 ), a substantial deficit on attention 6	
span and executive functions (|d|>1.5 ) and a moderate deficit in episodic memory(|d|>1 ). 7	
 8	
Figure 2:  Radar plot representing the statistically significant differences in cognitive 9	
performance between men and women with Down Syndrome (DS) on attention, memory, 10	
language and executive functioning components. Axis values indicate the performance in 11	
percentage relative to the women’s performance, which has been set to 100%. Men with DS 12	
performed significantly poorer than women in all four cognitive domains. 13	
 14	
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